Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial
Press ReleaseNicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial Several aqueous humor parameters stimulated by nitric oxide were statistically significant or trended in favor of NCX 470; likewise those that respond to prostaglandin analogsEpiscleral venous pressure changes did not show a trend vs. placeboSafety profile is consistent with that of the first Phase 3 trial, Mont BlancNCX 470 intraocular pressure lowering efficacy and safety...
Nasdaq GlobeNewswire
14/05/2025
Nyxoah Reports First Quarter Financial and Operating Results
REGULATED INFORMATIONNyxoah Reports First Quarter Financial and Operating ResultsCompany On Track for Anticipated PMA Approval in the Second Quarter of 2025Successfully Completed FDA Validation Requirements, Final Site Inspection in ProgressMont-Saint-Guibert, Belgium – May 14, 2025, 7am CET / 1am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep...
Nasdaq GlobeNewswire
14/05/2025
Preclinical insights into dosing for first-in-human in vivo liver-directed gene…
PRESS RELEASE Preclinical insights into dosing for first-in-humanin vivoliver-directed gene therapy for MMA delivered in an oral presentation at the ASGCT Annual MeetingMilan, ITALY – 14 May 2025– Genespire, a biotechnology company developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases, presented positive preclinical insights into dosing for the first-in-humanin vivoliver-directed gene therapy for methylmalonic acidemia (MMA) in an oral...
Nasdaq GlobeNewswire
14/05/2025
Cariflex Opens World's Largest Polyisoprene Latex Plant in Singapore, Following…
The inauguration ceremony was officiated by Dr Tan See Leng, Singapore's Minister for Manpower and Second Minister for Trade and Industry, and attended by H.E. Hong Jin Wook, Ambassador of the Republic of Korea, Mr Kim Jong Hyun, Chief Executive Officer of DL Chemical, Mr Ryu Sang Woo, Chief Executive Officer of Cariflex, Mr Prakash Kolluri, Member of Cariflex Board of Director and President, Polymer Business, Kraton, and Mr Lim Wey-Len, Executive Vice President of the Singapore Economic…
PR Newswire
14/05/2025
Noted Vaccine Researcher and Leader Kate O'Brien Awarded Sabin's Gold Medal…
O'Brien is a pioneering global health leader whose innovative work in vaccine access and policy has transformed immunization programs worldwide.“I am honored to award the Sabin Gold Medal to Dr. O'Brien for her extensive scientific and humanitarian work, which has significantly contributed to the development, licensure, and global distribution of critical immunizations,” says Amy Finan, Sabin's chief executive officer. “The breadth and scope of her work — in addition to her leadership in...
Nasdaq GlobeNewswire
14/05/2025
Liver Fibrosis Market to Witness Rapid Growth at a CAGR of ~24% During the…
Previously, liver steatosis was categorized as NAFLD and its more inflammatory subtype, NASH. However, to better reflect its metabolic roots, updated terminology such as MASLD and MASH has been introduced. These, along with other classifications like MASL, NASL, and MetALD, fall under the broader umbrella of Steatotic Liver Disease (SLD), offering improved diagnostic precision by emphasizing metabolic dysfunction. DelveInsight's assessment estimated around 8.3 million diagnosed prevalent cases…
PR Newswire
13/05/2025
Organoids Market Surges with Applications in Disease Modeling and Personalized…
Organoids Market revenue was USD 88 Million in 2022 and is forecast to a readjusted size of USD 290.8 Million by 2029 with a CAGR of 18.4% during the review period (2023-2029). Organoids Market revenue wasUSD 88 Millionin 2022 and is forecast to a readjusted size ofUSD 290.8 Millionby 2029 with a CAGR of 18.4% during the review period (2023-2029). Claim Your Free Report:https://reports.valuates.com/request/sample/QYRE-Auto-31J15902/Global_and_India_Organoids_Market Major...
PR Newswire
13/05/2025
Hagar hf.: Útboð á víxlum 20. maí 2025
Hagar hf. efna til útboðs á víxlum þriðjudaginn 20. maí 2025. Boðnir verða til sölu víxlar í nýjum 6 mánaða flokki HAGA251126.Fossar fjárfestingarbanki hf. hefur umsjón með útboðinu og kynningu þess fyrir hugsanlegum fjárfestum. Útboðið verður með hollenskri aðferð, þ.e. öll samþykkt tilboð bjóðast fjárfestum á hæstu flötu vöxtum sem tekið er. Víxlarnir eru gefnir út í 20 m.kr. nafnverðseiningum og sótt verður um skráningu þeirra í Kauphöll. Félagið áskilur sér rétt til þess að taka hvaða...
Nasdaq GlobeNewswire
13/05/2025
Behind the FDA's AI Push: A Growing Class of Public Healthcare Innovators
Major funding continues to pour into the AI healthcare sector, highlighted by Persivia's recent $107 million raise to scale its AI-powered platform. Looking ahead, analysts project that by 2035, artificial intelligence could inject an additional $461 billion into a global healthcare system already set to exceed $2.26 trillion. Major funding continues to pour into the AI healthcare sector, highlighted byPersivia'srecent$107 millionraise to scale its AI-powered platform. Looking...
PR Newswire
13/05/2025
Pharmaceutical Packaging Market worth $251.6 billion by 2034 - Exclusive Report…
Pharmaceutical Packaging Market Growth: According to an exhaustive report by The Research Insights, the Pharmaceutical Packaging Market is experiencing significant growth, driven by the increasing focus on environmental sustainability is transforming various industries including the pharmaceutical packaging market. Because consumers along with governmental bodies and healthcare providers prioritize sustainable practices more than ever before they now seek packaging solutions that serve…
PR Newswire
13/05/2025
Dental Anesthetics Market worth US$1.80 billion by 2030 with 4.0% CAGR |…
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=205221816 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=205221816 Browse in-depth TOC on "Dental Anesthetics Market" 200 - Tables49 - Figures244 - Pages By Based on Type,Articaine is expected to register the highest CAGR during the forecast period due to its many advantages over other types of anesthetics. The presence of a thiophene ring in articaine...
PR Newswire
13/05/2025
Cannabidiol Market to Hit $22.05 Billion by 2030 at CAGR 15.8% - Grand View…
Request a free sample copy or view report summary: Cannabidiol Market Request a free sample copy or view report summary:Cannabidiol Market Major players in the industry are focused on introducing CBD-infused products. Companies are exploring opportunities in international markets as the demand for CBD grows globally. Furthermore, they are investing in research and development to enhance the effectiveness and efficiency of their products, as well as to expand their offerings. The players...
PR Newswire
13/05/2025
Drug Device Combination Products Market worth US$379.17 billion by 2030 with…
Browse in-depth TOC on "Drug Device Combination Products Market" Browse in-depth TOC on "Drug Device Combination Products Market" 300 - Tables65 - Figures300 - Pages By Based on product type,the market for drug-device combination products can be categorized primarily by product type into injectable drug delivery devices, drug-eluting stents, inhalers, infusion pumps, transdermal patches, drug-eluting balloon catheters, and other product types. Among these, injectable...
PR Newswire
13/05/2025
SUQQU launches sustainable makeup compact with Eastman Cristal™ One
Eastman's Cristal One portfolio provides an end-of-life solution for cosmetics brands. The specialty PET is recognized by both the Association of Plastic Recyclers (APR) and RecyClass as being compatible with the resin identification code 1 (RIC1) stream, which means it can go directly into most municipal recycling systems. Eastman's Cristal One portfolio provides anend-of-life solutionfor cosmetics brands. The specialty PET is recognized by both the Association of Plastic Recyclers (APR)...
PR Newswire
13/05/2025
iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of…
– GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival– Based on totality of data, iTeos and GSK have agreed to terminate the belrestotug development program – iTeos has initiated a targeted review of strategic alternatives to maximize shareholder value WATERTOWN, Mass. and GOSSELIES, Belgium, May13, 2025(GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company...
Nasdaq GlobeNewswire
13/05/2025
Immatics Announces First Quarter 2025 Financial Results and Business Update
IMA203 PRAME Cell Therapy: Randomized-controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing and expected to complete enrollment in 2026IMA203 PRAME Cell Therapy: Phase 1b clinical trial ongoing with updated data in metastatic melanoma with substantially longer follow-up and additional uveal melanoma patients to be presented in an oral presentation at the 2025 ASCO Annual Meeting IMA203CD8 PRAME Cell Therapy (GEN2): Phase 1a clinical trial in solid tumors...
Nasdaq GlobeNewswire
13/05/2025
KAYAK reveals biggest savings and top trending locations for summer travellers
Asian adventure or sun-drenched Mediterranean?According to the data, Asia is having a moment this summer. Nearly half of all the destinations in the top 10 most-searched are in the region, with Bangkok and Manila leading as the top two – both with return flights that are the same or cheaper than last year. Asian adventure or sun-drenched Mediterranean?According to the data,Asiais having a moment this summer. Nearly half of all the destinations in the top 10 most-searched are in the...
PR Newswire
13/05/2025
Eligo Bioscience Awarded $5 Million to Advance Breakthrough Genetic Medicine…
This grant follows recent key milestones for Eligo, including the publication of its microbiome base-editing platform in Nature , securing multiple foundational patents covering in situ editing of the skin microbiome, and successfully expanding its Series B funding round to$35 million. This latest non-dilutive financial support strengthens Eligo's capacity to rapidly advance its clinical pipeline. Scaling up and advancing towards the clinic Building on the development of...
PR Newswire
13/05/2025
Transactions of Managers and Closely Associated Persons
Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition of 210,000 shares in Alvotech at ISK 1,277.38, by Alvogen Lux Holdings S.ár.l., the second largest shareholder in Alvotech. Alvogen Lux Holdings' largest shareholders are CVC (40%), Aztiq (30%) and Temasek (20%). Attachment Managers Transaction-CSSF Form-Alvogen Lux Holdings 2025-05-12
Nasdaq GlobeNewswire
13/05/2025
Wincomm Wins Best Choice Award at COMPUTEX 2025 for AI-Driven Surgical Panel PC
As European healthcare systems increasingly invest in AI-enabled surgery, the demand for computing platforms that combine clinical performance with safety and integration has grown. Wincomm's WMP-27T-PIS directly addresses this need, offering real-time AI processing, surgical imaging, and EMR support in a single, hygienic platform. As European healthcare systems increasingly invest inAI-enabled surgery, the demand for computing platforms that combine clinical performance with safety and...
PR Newswire
13/05/2025
Invitation to presentation of BioArctic's first quarter report for January -…
If you wish to participate via webcast, please use the link below. Via the webcast you will be able to ask written questions.Webcast: https://bioarctic.events.inderes.com/q1-report-2025/register If you wish to participate via webcast, please use the link below. Via the webcast you will be able to ask written questions. Webcast:https://bioarctic.events.inderes.com/q1-report-2025/register If you wish to participate via teleconference, please register on the link below. After registration...
PR Newswire
13/05/2025
EnteroBiotix Presents Positive Data in Liver Cirrhosis at EASL 2025
EnteroBiotix Presents Positive Data in Liver Cirrhosis at EASL 2025EBX-102 was well tolerated and showed multiple positive trends over placeboFindings support progression to a Phase 2b trial Glasgow, Scotland – 13 May 2025.EnteroBiotix Limited ('EnteroBiotix)' a clinical-stage biotechnology company developing best-in-class therapies for gut health, today announced positive results from its Phase 1b clinical trial evaluating EBX-102, the Company's next-generation oral full-spectrum...
Nasdaq GlobeNewswire
13/05/2025
The Galien Foundation Announces 2025 Prix Galien UK Award Candidates for "Best…
"As Chair of the Prix Galien UK Committee, I am honoured to announce this year's exceptional candidates across six distinguished categories. These individuals and organisations exemplify excellence in healthcare innovation and demonstrate a steadfast commitment to advancing patient outcomes. Their contributions are shaping the future of medicine and reinforcing the vital role of scientific progress in improving human health," said Professor Sir Munir Pirmohamed, David Weatherall Chair…
PR Newswire
13/05/2025
SciBase: Interim report
The first quarter in figures The first quarter in figures Important events during the quarter Important events after the end of the period This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET onMay 13, 2025. This interim report report has not been subject to review by the Company's...
PR Newswire
13/05/2025
Altri Comunicati